Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Medicinal Products

Dáil Éireann Debate, Thursday - 26 February 2026

Thursday, 26 February 2026

Ceisteanna (552)

Ken O'Flynn

Ceist:

552. Deputy Ken O'Flynn asked the Minister for Health whether formal commercial negotiations between the HSE Corporate Pharmaceutical Unit and the relevant marketing authorisation holders in respect of tirzepatide and semaglutide are currently active; whether any price proposal has been received following completion of the HTA processes; whether any budget ceiling or access cap has been set as a matter of Departmental policy; and if she will make a statement on the matter. [15882/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has sole statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Roinn